Diabetes

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

By

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed diabetes patients tripled during that same time period.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Diabetes costliest among non-specialty Rx

Diabetes costliest among non-specialty Rx

By

Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.

Study links patient confidence to Rx adherence

Study links patient confidence to Rx adherence

By

Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.

Louisiana sends Takeda $9-billion Actos bill

The drugmaker is accused of burying cancer risks associated with the diabetes medication.

FDA won't review Afrezza until July

The regulator has put off the inhaled insulin's PDUFA date by three months.

Boerhinger funds ADA initiative

The three-year collaboration includes $1.5 million for chronic kidney disease research.

EU may expand Tresiba indication

The new indication would mean Tresiba and Victoza could be prescribed in tandem.

EMA advisory panel backs Lilly/BI's empagliflozin

EMA advisory panel backs Lilly/BI's empagliflozin

By

The Committee for Medicinal Products for Human Use endorses the SGLT2 inhibitor. The FDA refused to approve the drug earlier this month because of manufacturing issues.

CRL stalls Lilly/BI's empagliflozin

CRL stalls Lilly/BI's empagliflozin

By

The issue: Boehringer's manufacturing site. The FDA is not asking for new clinical studies.

Regulators split difference over diabetes meds

Regulators split difference over diabetes meds

By

Spurred by a 2013 report of a possible link between drugs like Merck's Januvia and pancreatitis or pancreatic cancer, the FDA and EMA said they have not found a definitive link but will continue to collect data.

Lilly's GLP-1 contender takes a step forward

Lilly's GLP-1 contender takes a step forward

By

Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.

Merck latest rival in race to copy Lantus

Merck latest rival in race to copy Lantus

By

Merck announced this week that its insulin glargine biosimilar, being developed with Samsung and Biogen Idec, would soon enter Phase-III trials.

Diabetes lures pharma to the Gulf

Governments have been courting industry investment, reports the Wall Street Journal.

FDA takes closer look at AZ's saxagliptin

FDA takes closer look at AZ's saxagliptin

By

The regulator says a 2013 study that indicated a higher rate of heart failure compared to placebo—but not death—has prompted a second look at the diabetes medication.

Engaging mobile diabetes management

Engaging mobile diabetes management

By

A six-month pilot program at the University of Chicago improved glycemic control and engaged patients and HCPs through one key device: a mobile phone.

Sanofi muddles through 2013

Sanofi muddles through 2013

By

Constant exchange rates provide a positive framework for quarterly and year-end totals, whereas straight percentages indicate lower sales.

Big Pharma puts $250M towards disease collaboration

Ten pharma companies will share money and biomarker research under an NIH collaboration.

Sanofi sues to protect Lantus

The suit stalls Eli Lilly's biosimilar version of insulin glargine.

Lilly says 2014 will not be "trough year"

Lilly says 2014 will not be "trough year"

By

Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.

Boehringer, Zealand reframe diabetes pact

The companies are changing the key compound.

Novo sued over generic Prandin claim

Three drug purchasing companies have taken the Denmark drugmaker to court in the US. The charge: wrongfully keeping generics off the market.

FDA approves AZ's Farxiga (dapagliflozin)

FDA approves AZ's Farxiga (dapagliflozin)

By

AZ's delayed diabetes pill was given the FDA nod today, the second treatment of its kind available in the US behind J&J's Invokana.

Lilly tees up 2014 expectations

Lilly tees up 2014 expectations

By

The company releases 2014 guidance Tuesday, but signals from the previous 12 months indicate the Indiana drugmaker is determined to hit its $20-billion earnings target, patent losses be damned.

Nodding to bloggers, Lilly digitizes content

Nodding to bloggers, Lilly digitizes content

By

The move to digitize a series of books it co-created with Disney for kids with type 1 diabetes was spurred by a meeting with the online diabetes community.

BMS breaks free of diabetes

BMS breaks free of diabetes

By

BMS is giving up its stake of the AstraZeneca diabetes joint venture for $2.7 billion up front, and future milestone payments.

Janssen gets diabetes CRL

The FDA wants more data for the proposed canagliflozin-metformin medication mix.

BMS pulls new diabetes med in Germany

The drugmaker and partner AstraZeneca say they can't find a comfortable pricing arrangement with German insurers.

Novo compounds Tresiba troubles

Danish police are investigating the drugmaker over its decision to wait two days before announcing the FDA's February rejection.

BMS, AZ prep for FDA panel, bladder cancer may be topic

BMS, AZ prep for FDA panel, bladder cancer may be topic

By

FDA panel briefing documents indicate concern remains over bladder cancer, as the drug dapagliflozin undergoes a second review Thursday.

Email Newsletters